Abstract
PET has emerged as a powerful diagnostic tool for the evaluation of cancer patients. Currently, most of these studies are performed with the glucose analog 18F-FDG, which has been shown to accumulate avidly in most tumors. 18F-FDG PET is now routinely used in the diagnosis, staging, and posttherapy evaluation of oncologic patients. After reading this paper, the reader should understand the physiologic basis of using 18F-FDG in patients with different tumors, describe the role of this radiopharmaceutical in the management of oncologic patients, and identify those malignancies for which 18F-FDG has proved to be effective in diagnosis and follow-up.
Jump to section
Related Articles
Cited By...
- Fifty Years of Radiopharmaceuticals
- Paraneoplastic thrombus or relapse of a pulmonary artery sarcoma?
- High-Contrast PET of Melanoma Using 18F-MEL050, a Selective Probe for Melanin with Predominantly Renal Clearance
- Reduction of the Ring Size of Radiolabeled Lactam Bridge-Cyclized {alpha}-MSH Peptide, Resulting in Enhanced Melanoma Uptake
- 99mTc- and 111In-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptides as Imaging Probes for Primary and Pulmonary Metastatic Melanoma Detection
- Utility of 18F-FDG PET in Evaluating Cancers of Lung
- 3'-18F-Fluoro-3'-Deoxy-L-Thymidine: A New Tracer for Staging Metastatic Melanoma?
- Direct Imaging of Exercise-Induced Myocardial Ischemia With Fluorine-18-Labeled Deoxyglucose and Tc-99m-Sestamibi in Coronary Artery Disease
- Glucose Metabolism in Cancer: EVIDENCE THAT DEMETHYLATION EVENTS PLAY A ROLE IN ACTIVATING TYPE II HEXOKINASE GENE EXPRESSION